Local Housewife and effective ☎️ 8250192130 🍉🍓 Sexy Girls VIP Call Girls Chan...
ESAs Therapy: Friend or Foe? - Dr. Gawad
1. ESAs Therapy: Friend or Foe?
Mohammed Abdel Gawad
Nephrology Specialist
Kidney & Urology Center (KUC)
Alexandria – EGY
drgawad@gmail.com
7th International Conference of Mansoura University Nephrology Unit
29-30, March, 2017
2. ESAs Therapy use to correct
Hb level: Friend or Foe?
ESAs Therapy: Friend or Foe?
3. Talk Outline
• Hypertension
• Vascular diseases:
• Vascular Thrombo-embolism
• Stroke
• Myocardial infarction (& cardiovascular outcomes)
• Malignancy
• Quality of life
• How to use ESAs?
4. Talk Outline
• Hypertension
• Vascular diseases:
• Vascular Thrombo-embolism
• Stroke
• Myocardial infarction (& cardiovascular outcomes)
• Malignancy
• Quality of life
• How to use ESAs?
6. Expert Opin Drug Saf 2016; 15: 1021–1030
Nephrol Dial Transplant (2016) 00: 1–21
J Am Heart Assoc. 2013 Apr;2(2):e000128
ESA
↑ intra-
cytosolic
Ca
Enhanced
vascular
alpha
adrenergic
sensitivity
↑ plasma
endothelin
levels
↓NO
production
Arterial
remodeling
Activation
of RAAS
Elevation of
the
thromboxane
prostacyclin
ratio
Higher
blood
viscosity
ESA therapy induced
hypertension:
Pathogenesis
• ESA indirect effect:
Related to Hb level
• ESA direct effect:
Related to action of ESA
on vascular system and
humoral factors
7. Expert Opin Drug Saf 2016; 15: 1021–1030
Nephrol Dial Transplant (2016) 00: 1–21
J Am Heart Assoc. 2013 Apr;2(2):e000128
ESA therapy induced
hypertension:
Pathogenesis
• ESA indirect effect:
Related to Hb level
• ESA direct effect:
Related to action of ESA
on vascular system and
humoral factors
ESA therapy induced
hypertension:
Who at risk?
● Intravenous administration
(versus subcutaneous)
● Hemodialysis (versus CAPD or
no dialysis)
● Family history of hypertension
8. Expert Opin Drug Saf 2016; 15: 1021–1030
Nephrol Dial Transplant (2016) 00: 1–21
J Am Heart Assoc. 2013 Apr;2(2):e000128
ESA
↑ intra-
cytosolic
Ca
Enhanced
vascular
alpha
adrenergic
sensitivity
↑ plasma
endothelin
levels
↓NO
production
Arterial
remodeling
Activation
of RAAS
Elevation of
the
thromboxane
prostacyclin
ratio
Higher
blood
viscosity
ESA therapy induced
hypertension:
Pathogenesis
• ESA indirect effect:
Related to Hb level
• ESA direct effect:
Related to action of ESA
on vascular system and
humoral factors
Kidney Blood Press Res. 2012;35(2):71-6
ESA therapy induced
hypertension:
Who at risk?
The CC genotype of the EPO
gene at position 3434
9. Ann Intern Med. 2010 Jul 6;153(1):23-33.
Targeting
higher
hemoglobin
levels
increases
risks for
hypertension
11. Am J Kidney Dis. 2013 Jan;61(1):44-56
31 trials (12,956 patients)
High first-3-month mean
ESA dose (per epoetin
alfa–equivalent 10,000-
U/wk increment)
vs
lower doses
12. Kidney International Supplements (2012) 2, 283–287
3.2: In initiating and maintaining ESA
therapy, we recommend balancing the
potential benefits of reducing blood
transfusions and anemia-related
symptoms against the risks of harm in
individual patients (e.g., stroke,
vascular access loss, hypertension).
13. Talk Outline
• Hypertension
• Vascular diseases:
• Vascular Thrombo-embolism
• Stroke
• Myocardial infarction (& cardiovascular outcomes)
• Malignancy
• Quality of life
• How to use ESAs?
14. Talk Outline
• Hypertension
• Vascular diseases:
• Vascular Thrombo-embolism
• Stroke
• Myocardial infarction (& cardiovascular outcomes)
• Malignancy
• Quality of life
• How to use ESAs?
16. ESA therapy can
contribute to
vascular access
stenosis or occlusion
by promoting
intimal hyperplasia
and thrombosis
Clin Drug Investig. 2016 Jun;36(6):421-31
17. Talk Outline
• Hypertension
• Vascular diseases:
• Vascular Thrombo-embolism
• Stroke
• Myocardial infarction (& cardiovascular outcomes)
• Malignancy
• Quality of life
• How to use ESAs?
18. Talk Outline
• Hypertension
• Vascular diseases:
• Vascular Thrombo-embolism
• Stroke
• Myocardial infarction (& cardiovascular outcomes)
• Malignancy
• Quality of life
• How to use ESAs?
19. N Engl J Med. 1998;339(9):584.
14 g/dL
10 g/dL
Normal Hematocrit Trial (NHT) 1233 patients
Both synthetic grafts and natural fistulae clotted more often
in the normal hematocrit group
22. Kidney International Supplements (2012) 2, 283–287
3.2: In initiating and maintaining ESA
therapy, we recommend balancing the
potential benefits of reducing blood
transfusions and anemia-related
symptoms against the risks of harm in
individual patients (e.g., stroke,
vascular access loss, hypertension).
23. Talk Outline
• Hypertension
• Vascular diseases:
• Vascular Thrombo-embolism
• Stroke
• Myocardial infarction (& cardiovascular outcomes)
• Malignancy
• Quality of life
• How to use ESAs?
24. Talk Outline
• Hypertension
• Vascular diseases:
• Vascular Thrombo-embolism
• Stroke
• Myocardial infarction (& cardiovascular outcomes)
• Malignancy
• Quality of life
• How to use ESAs?
25. CHOIR: N Engl J Med. 2006; 355:2085-2098
CREAT: N Eng J Med. 2006;335:2071–84
TREAT: N Eng J Med. 2009;361:2019–32
But no statistical
difference in stroke
26. Kidney International Supplements (2012) 2, 283–287
3.2: In initiating and maintaining ESA
therapy, we recommend balancing the
potential benefits of reducing blood
transfusions and anemia-related
symptoms against the risks of harm in
individual patients (e.g., stroke,
vascular access loss, hypertension).
27. Kidney International Supplements (2012) 2, 283–287
3.3: We recommend using ESA therapy
with great caution, if at all, in CKD
patients with active malignancy—in
particular when cure is the anticipated
outcome—(1B), a history of stroke
(1B), or a history of malignancy (2C).
40. This seems particularly true for solid tumors and, regarding
tumor growth, especially for patients with head and neck
cancer receiving radiotherapy only
Clin Drug Investig. 2016 Jun;36(6):421-31
41. TREAT: N Eng J Med. 2009;361:2019–32
Higher risk of dying from cancer
among the patients with a
previous malignancy at least
5 years before randomization
who were treated with
darbepoetin alfa compared with
placebo
42. Kidney International Supplements (2012) 2, 283–287
3.3: We recommend using ESA therapy
with great caution, if at all, in CKD
patients with active malignancy—in
particular when cure is the anticipated
outcome—(1B), a history of stroke
(1B), or a history of malignancy (2C).
43. In malignancy: ESAs should be administered at the
lowest possible dose and the treatment should
increase the Hb level to the lowest level that avoids
blood transfusions
Clin Drug Investig. 2016 Jun;36(6):421-31
44. Leuk Res. 2010 Aug;34(8):981-5
n = 192
p < 0.0095) in
responders as
compared to
non-responders
46. Talk Outline
• Hypertension
• Vascular diseases:
• Vascular Thrombo-embolism
• Stroke
• Myocardial infarction (& cardiovascular outcomes)
• Malignancy
• Quality of life
• How to use ESAs?
47. Talk Outline
• Hypertension
• Vascular diseases:
• Vascular Thrombo-embolism
• Stroke
• Myocardial infarction (& cardiovascular outcomes)
• Malignancy
• Quality of life
• How to use ESAs?
48. Ann Intern Med. 2016 Apr 5;164(7):472-8
A meta-analysis
including 17 RCT
Hb levels of 9 to
12 g/dL compared
with Hb levels
>11 g/dL
7616 CKD and
2433 dialysis
patients
49. A meta-analysis
including 17 RCT
Hb levels of 9 to
12 g/dL compared
with Hb levels
>11 g/dL
7616 CKD and
2433 dialysis
patients
Ann Intern Med. 2016 Apr 5;164(7):472-8
50. A meta-analysis
including 17 RCT
Hb levels of 9 to
12 g/dL compared
with Hb levels
>11 g/dL
7616 CKD and
2433 dialysis
patients
Ann Intern Med. 2016 Apr 5;164(7):472-8
51. Kidney International Supplements (2012) 2, 283–287
3.4.4 & 3.5.2:
Individualization during initiation and
maintenance of therapy is reasonable
as some patients may have
improvements in quality of life
53. Anemia may not be the dominant
factor contributing to diminished HRQOL
Other medical (adequacy, malnutrition, inflammation,
and comorbidities) and patient (symptoms, mental
health, and coping) factors should be concurrently
addressed.
Curr Opin Nephrol Hypertens. 2017 Mar 16.
54. Talk Outline
• Hypertension
• Vascular diseases:
• Vascular Thrombo-embolism
• Stroke
• Myocardial infarction (& cardiovascular outcomes)
• Malignancy
• Quality of life
• How to use ESAs?
55. Talk Outline
• Hypertension
• Vascular diseases:
• Vascular Thrombo-embolism
• Stroke
• Myocardial infarction (& cardiovascular outcomes)
• Malignancy
• Quality of life
• How to use ESAs?
56. Kidney International Supplements (2012) 2, 283–287
3.8.1: We recommend determining
the initial ESA dose using the patient’s
Hb concentration, body weight, and
clinical circumstances. (1D)
57. Kidney International Supplements (2012) 2, 283–287
3.13.2: In patients with ESA hypo-
responsiveness, we suggest avoiding
repeated escalations in ESA dose beyond
double the initial weight-based dose. (2D)
58. Kidney International Supplements (2012) 2, 283–287
Start appropriate dose and go slow:
In general, the objective of initial ESA
therapy is a rate of increase in Hb
concentrations of 1.0 to 2.0 g/dl/month.
59. Kidney International Supplements (2012) 2, 283–287
ESAs
Maintenance
In general
11.5
Individualized
>11.5
In all adults
not >13
Higher risk of stroke, all
cause, cardiovascular
morbidity & mortality
61. Home Messages
• Hb normalization increases risk of HTN
• Hb normalization increases risk of Vascular thrombo-embolism
• Hb normalization increases risk of Stroke, although re-analysis
of TREAT showed no risk, and there is a weak evidence that
ESAs use in dialysis patients may be protective
62. Home Messages
• Hb normalization increases risk of cardiac end points, but no
statistical difference on MI
• Use ESAs cautiously with malignancy, but there may be a
benefit of ESAs with myelodysplastic syndrome
• Individualize ESAs therapy according to QOL especially in
young age patients
63. Home Messages
ESAs Therapy: Friend or Foe?
BW adjusted dose
Go slow raise / month
Monitor Hb
Don’t normalize Hb
Friend
High doses (>2X adjusted BW)
Rapid raise of Hb / month
No Hb monitoring
Normalized Hb
Foe